Weight-Loss drugs may boost your sex drive, study hints
NCT ID NCT05598008
First seen Jan 03, 2026 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This study looked at whether GLP-1 analogues (like Ozempic or Wegovy) combined with lifestyle changes can improve sexual desire in overweight or obese men and women. 85 participants were followed to measure changes in sexual thoughts, activity, and overall sexual health. The goal is to understand how these popular weight-loss drugs might affect sexuality beyond just weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Basel, Endocrinology, Diabetes and Metabolism
Basel, 4031, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 analogues (e.g., liraglutide, semaglutide)
What this could lead to
If successful, this could show that GLP-1 drugs help improve sexual desire in overweight or obese people, offering a new benefit of these medications.
What could go wrong
This is a small, completed study with only 85 participants. Results may not apply to everyone, and the open-label design (no placebo) can bias outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.